![](https://financialmodelingprep.com/image-stock/EFTR.png)
eFFECTOR Therapeutics, Inc. (EFTR)
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
$188.18K
Dr. Stephen T. Worland Ph.D.
12.00
Solana Beach, CA
Mar 01, 2021
0.00
$-12.57
0.61
1.03
-21,376.54%
-0.00
-0.00
0.27
1.60
0.99
-127.64%
2,178.33%
Similar stocks (5)
Jasper Therapeutics, Inc.
JSPR
RenovoRx, Inc.
RNXT
Indaptus Therapeutics, Inc.
INDP
Ensysce Biosciences, Inc.
ENSC
Virpax Pharmaceuticals, Inc.
VRPX
Similar stocks (5)
Jasper Therapeutics, Inc.
JSPR
RenovoRx, Inc.
RNXT
Indaptus Therapeutics, Inc.
INDP
Ensysce Biosciences, Inc.
ENSC
Virpax Pharmaceuticals, Inc.
VRPX